Purchase Order 36C24226P0155

The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 2, awarded a firm fixed-price purchase order to Pantherx Specialty, LLC (doing business as Pantherx Specialty Pharmacy) for TARPEYO 4mg (budesonide), a specialty pharmaceutical product used to treat immunoglobulin A nephropathy in veterans. The contract, valued at $10,896.98, was awarded on November 10, 2025, with an ultimate completion date of December 10, 2025. The award carries no set-aside designation and will be performed in Pittsburgh, Pennsylvania, where the contractor is based. Pantherx Specialty, a for-profit limited liability company and subsidiary of Centene Corporation, specializes in providing rare disease medications and customized pharmaceutical solutions to federal healthcare agencies.

This purchase order aligns with Pantherx Specialty's established role as a targeted provider of specialized medications to the VA and other federal agencies. The contractor has a demonstrated history of delivering firm fixed-price pharmaceutical contracts, typically ranging from $10,000 to $43,869, to support the medical needs of veterans and federal beneficiaries. As the sole prime contractor on this transaction with no subcontractor involvement noted, Pantherx Specialty will furnish the medication directly to VISN 2, which comprises VA medical facilities serving veterans across the northeastern United States.